-+ 0.00%
-+ 0.00%
-+ 0.00%

Cantor Fitzgerald Maintains Overweight on Legend Biotech, Lowers Price Target to $74

Benzinga·12/17/2025 14:55:14
Listen to the news
Cantor Fitzgerald analyst Eric Schmidt maintains Legend Biotech (NASDAQ:LEGN) with a Overweight and lowers the price target from $75 to $74.